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1. Introduction 
Erythropoietin (Epo) is a glycoprotein hormone that controls 
the erythropoiesis, or red blood cell (RBC) production. It is about a 
cytokine (protein signaling molecule) for rbc precursors production in 
bone marrow. This is the reason that Epo implicates over 29,116 known 
biomedical studies. 1003 (3.44%) at least of these studies concern 
experiments of tissue ischemia-reperfusion (IR). Further research 
interests occupy whether Epo is able to reverse any injuries of targeted 
IR tissues as well adjacent organs and of course the patients’ health. The 
investigation of basic answers as, its reaction velocity, the time of 
administration and the the dosage height fill in this context. The benefits 
of this cytokine may be further than the original action of Epo. However, 
the more specific matters, the fewer related reports are found. A numeric 
outcome of the Epo efficacy was yielded by a meta-analysis of 32 
published serum variables. These outcomes from the same experimental 
setting, for the same endpoints (Table 1).  
The certain aim of this biomedical work was to test the effect 
of Epo on a rat model and mainly in an ovarian IR protocol. The Epo 
effect was particularly tested on mean ovarian epithelium edema (OE) 
lesions.  
 
2. Materials and methods 
2.1 Pats preparation 
The vet Address of East Attiki Prefecture licensed this 
experimental work by 3693/12-11-2010 No and 14/10-1-2012 No 
decisions. ELPEN Pharmaceuticals Co Inc. S.A. granted all substances, 
equipment and consumable. Humanistic care was adopted for the female 
albino Wistar rats. This care started already pre-experimentally by 7 
days housing in laboratory with ad libitum diet. Intra-experimental 
prenarcosis of animals, continuous general anesthesia [1-7], 
electrocardiogram, acidometry, oxygen supply and post-experimental 
euthanasia were followed. The rats were randomly classified into four 
groups of 10 animals each one. These 4 groups were submitted into 
preceded ischemia of 45 min induced by laparotomic clamping of 
inferior aorta over the renal arteries. Then, the clamp removal restored 
the reperfusion after inferior aorta patency reestablishment. 
Reperfusion lasted 60 min for group A, 120 min for group B, 60min along 
with Epo intravenous (IV) administration for group C and 120 min along 
with Epo IV administration for group D. The dosage height for cytokine 
was 10 mg/kg body mass of animal. Epo administration at the time of 
reperfusion set was inserted through inferior vena cava catheter. The OE 
lesions evaluations were performed 60 min after reperfusion for A and C 
groups and 120 min after reperfusion for B and D groups. The mean of 
the forty (40) female Wistar albino rats mass used was 247.7 g [Standard 
Deviation (SD): 34.99172 g], with min weight 165 g to max weight 320 g. 
Thus, pathologic e v a l u a t i o n 8 and classification of OE findings was 
outcome as scores: 0 for none lesions, 1 for mild ones, 2 for moderate 
ones and 3 for serious ones. The previous classification was transformed 
as follows: (0-0.499) without OE lesions, (0.5- 1.499) the mild ones, (1.5 -
2.499) the moderate ones and (2.5-3) the serious ones since score ranges 
replaced the point o n e s . The OE scores were evaluated by the 1st 
Pathology Department of Clinical – Laboratory Sector in Faculty of 
Medicine of Athens University. 
2.2 The model of ovarian ischemia-reperfusion 
2.2.1 Control branch 
This branch included 20 control rats of mean weight 252.5 g 
[SD: 39.31988 g] submitted into ischemia for 45 min followed by 
reperfusion. The 2 sub-branches consisted of the group A reperfused by 
60 min for 10 controls rats of mean weight 243 g [SD: 45.77724 g] and 
mean mild OE lesions score 0.7 [SD: 0.8232726] and the group B 
reperfused by 120 min for 10 controls rats of mean weight 262 g [SD: 
31.10913 g] and mean mild OE lesions score 1.1 [SD: 0.9944289] (Table 
2).   
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2.2.2 Erythropoietin branch 
This branch included 20 Epo rats of mean weight 242.9 g [SD: 
30.3105 g] submitted into ischemia for 45 min followed by both 
reperfusion and 10 mg Epo/kg body weight IV administration. The 2 
sub-branches consisted of the group C reperfused by 60 min for 10 Epo 
rats of mean weight 242.8 g [SD: 29.33636 g] and mean mild OE lesions 
score 0.5 [SD: 0.7071068] and the group D reperfused by 120 min for 10 
Epo rats of mean weight 243 g [SD: 32.84644 g] and mean mild OE 
lesions score 0.7 [SD: 0.8232726] (Table 2).   
2.3 Statistical analysis 
The statistical analysis was performed twice. The one way 
included the statistical standard t-tests and Wilcoxon signed-rank test 
for mass and OE lesions scores groups respectively (Table 3). If any 
probable significant difference among OE lesions scores was revealed, it 
would be tested whether along any respective probable significant mass 
one exists (Table 3). The other way was the generalized linear models 
(glm). They included the OE lesions scores as dependant variable and the 
Epo administration or no, the reperfusion time and their interaction as 
the 3 independent variables. Rats' mass could be probably a confusing 
factor, e.g. the more obese rats to have higher OE lesions scores. This 
assumption was rejected since the insertion of rats’ mass as independent 
variable at glm, yielded a non significant correlation with OE lesions 
scores (p=1.0000). The statistical tests were performed by Stata 6.0 
statistical software [Stata 6.0, StataCorp LP, Texas, USA]. 
 
3. Results 
The glm resulted in: Epo administration non-significantly 
decreased the OE scores by 0.3 without lesions [-0.8356043 - 
0.2356043] (p=0.2639). This finding was in accordance with the results 
of Wilcoxon signed-rank test (p=0.2967). Reperfusion time kept non-
significantly increased the OE by 0.3 without lesions [-0.2356043 - 
0.8356043] (P= 0.2639), approximately in accordance with Wilcoxon 
signed-rank test; increased by 0.4 without lesions (-1.014921 - 
0.214921) (p= 0.2475). However, erythropoietin administration and 
reperfusion time together non-significantly decreased the OE scores by 
0.1272727 without lesions [-0.4530022 - 0.1984567] (p=0.4339). 
Reviewing the above and table 3, the tables 4 and 5 sum up concerning 
the alteration influence of Epo in connection with reperfusion time.  
 
Table 1: The erythropoietin (Epo) influence (±SD) on the levels of some seric1 variables concerning reperfusion (rep) time 
Variable 1h rep p-value 1.5h rep p-value 2h rep p-value interaction of Epo and rep p-value 
White BCC          +24.01%+13.38% 0.1012 +22.09%+9.11% 0.0163 +20.17%+12.94% 0.0902 +14.63%+5.40% 0.0080 
Red BCC +1.45%+3.31% 0.6589 +0.37%+3.02% 0.9048 -0.70%+4.68% 0.8844 +0.81%+1.79% 0.6446 
Hematocrit +0.14%+2.89% 0.9626 -0.61%+2.37% 0.8072 -1.37%+4.05% 0.7485 +0.24%+1.38% 0.8586 
Hemoglobi6 +4.09%+5.20% 0.3350 +2.15%+2.63 0.4527 +0.20%+5.08% 0.9584 +1.31%+1.59% 0.3984 
MCH +0.01%+1.29% 0.9904 +0.67%+0.80% 0.3549 +1.34%+1.08% 0.1509 -0.36%+0.47% 0.4430 
MCV5 +0.01%±1.08% 0.9904 +0.56%±0.66% 0.3549 +1.12%±0.91% 0.1509 +0.30%±0.39% 0.4430 
MCHC3 +1.82%+0.56% 0.0076 +1.73%+0.50% 0.0016 +1.65%+0.92% 0.0721 +0.89%+0.31% 0.0061 
RbcDW -1.85%+4.24% 0.6703 -1.64%+2.53% 0.5159 -1.43%+3.34% 0.6078 -1.06%+1.43% 0.4733 
Plt C2 -7.32%+13.11% 0.5219 -2.14%+8.04% 0.7581 +3.04%+10.78% 0.7204 -0.16%+4.76% 0.9725 
Platelet DW +1.60%+0.80% 0.0765 +1.36%+0.58% 0.0205 +1.13%+0.74% 0.1152 +0.37%+0.37% 0.0615 
Platelet-crit -16.47%+10.40% 0.0921 -13.74%+7.01% 0.0158 -11.01%+7.34% 0.0882 -6.88%+3.69% 0.0615 
Glucose7 +0.75%+8.11% 0.9307 +5.59%+6.46% 0.3208 +10.44%+10.99% 0.3491 +4.94%+3.81% 0.1892 
Urea +21.42%+7.84% 0.0115 +20.11%+7.25% 0.0059 +18.80%+9.44% 0.0709 +15.64%+4.04% 0.0003 
Creatinine -0.10%+9.78% 0.9904 -4.84%+5.78% 0.3721 -9.59%+7.74% 0.1509 -2.62%+3.49% 0.4430 
Uric acid                        +10.13%+15.10% 0.4917 +15.86%+10.21% 0.1408 +21.59%+15.45% 0.1940 +9.33%+6.16% 0.1264 
Total protei                -0.02%+2.47% 0.9904 -1.27%+1.51% 0.3721 -2.52%+2.03% 0.1509 -0.68%+2.48% 0.4430 
Albumins -4.61%+4.21% 0.2530 -9.28%+3.20% 0.0054 -13.96%+5.03% 0.0095 -5.37%+2.73% 0.0072 
ALT +18.89%+12.42% 0.1372 +7.63%+18.94% 0.6396 -3.63%+25.19% 0.8617 +8.03%+11.36% 0.4698 
AST +29.53%+9.72% 0.0096 +26.71%+13.17% 0.0235 +23.89%+21.59% 0.1709 +19.73%+7.70% 0.0119 
γGT -19.35%+18.58% 0.2362 -12.70%+13.11% 0.3541 -6.06%+19.96% 0.7800 -4.62%+7.97% 0.5534 
ALP   +0.20%+18.57% 0.9904 +10.70%+12.78% 0.3549 +21.20%+17.11% 0.1509 +5.79%+7.72% 0.4430 
ACP          +0.06%+5.79% 0.9904 +3.11%+3.71% 0.3172 +6.16%+4.97% 0.1509 +1.68%+2.23% 0.4430 
CPK +0.15%+14.09% 0.9904 +7.91%+9.44% 0.3549 +15.67%+12.65% 0.1509 +4.28%+5.70% 0.4430 
CK-MB4 +0.08%+7.90% 0.9904 +4.28%+5.11% 0.3721 +8.49%+6.85% 0.1509 +2.32%+3.09% 0.4430 
LDH +0.08%+7.92% 0.9904 +4.48%+5.35% 0.3549 +8.89%+7.17% 0.1509 +2.42%+3.22% 0.4430 
Sodium +0.72%+0.74% 0.3054 +0.21%+0.63% 0.7136 -0.29%+1.09% 0.7670 -0.11%+0.38% 0.7531 
Potassium -6.17%+4.94% 0.1540 -2.21%+3.66% 0.5134 +1.74%+5.43% 0.7299 +0.18%+2.22% 0.9338 
Calcium 0.28%+1.19% 0.8065 -0.56%+1.13% 0.5761 -1.41%+2.08% 0.4100 -0.34%+0.68% 0.6095 
Phosphorus +1.92%+5.25% 0.6982 +3.95%+3.35% 0.2100 +5.98%+4.81% 0.2930 +2.45%+2.01% 0.2168 
Magnesium +1%+6.20% 0.8596 -1.09%+3.34% 0.7248 -3.19%+3.90% 0.3729 -0.19%+1.93% 0.9197 
Amylase +6.50%+9.15% 0.4161 +5.04%+6.12% 0.3831 +3.59%+8.42% 0.6649 +4.36%+3.65% 0.2258 
Progesteron -0.20%+18.65% 0.9904 -8.86%+10.58% 0.3549 -17.53%+14.15% 0.1509 -4.79%+6.39% 0.4430 
Μean +2.15%+9.92% 0.5824 +2.67%+9.06% 0.3645 +3.2%+10.34% 0.3583 +2.26%+5.91% 0.4041 
 
Table 2: Weight and ovarian epithelium edema (OE) score mean levels and Std. Dev. of groups 
Groups Variable Mean Std. Dev 
Α Weight 243 g 45.77724 g 
OE mild 0.7 0.8232726 
B Weight 262 g 31.10913 g 
OE mild 1.1 0.9944289 
C Weight 242.8 g 29.33636 g 
OE mild 0.5 0.7071068 
D Weight 243 g 32.84644 g 
OE mild 0.7 0.8232726 
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Table 3: Statistical significance of mean values difference for groups (DG) after statistical paired t test application for weight and Wilcoxon 
signed-rank test for scores 
DG Variable Difference p-value 
Α-Β Weight -19 g 0.2423 
OE without lesions -0.4 0.3307 
Α-C Weight 0.2 g 0.9900 
OE without lesions 0.2 0.6371 
Α-D Weight 0 g 1.0000 
OE without lesions 0 1.0000 
Β-C Weight 19.2 g 0.0478 
OE mild 0.6 0.1511 
Β-D Weight 19 g 0.2113 
OE without lesions 0.4 0.3095 
C-D Weight -0.2 g 0.9883 
OE without lesions -0.2 0.6190 
 
Table 4: The decreasing influence of erythropoietin in connection with reperfusion time 
   p-values  
Decrease 95% c. in. Reperfusion time Wilcoxon glm 
without lesions 0.2     -0.9210105 - 0.5210105 1h 0.6371 0.5673 
without lesions 0.3     -0.8356043 - 0.2356043 1.5h 0.2967 0.2639 
without lesions 0.4 -1.257698 - 0.4576978 2h 0.3095 0.3402 
without lesions -0.3    -0.2356043 - 0.8356043 reperfusion time  0.2639 
without lesions -0.4    -1.014921 – 0.214921 reperfusion time 0.2475  
without lesions  0.1272727 -0.4530022 -0.1984567 interaction 0.4339 
 
Table 5: Concise presence of the decreasing influence of erythropoietin in connection with reperfusion time 
Decrease 95% c. in. Reperfusion time p-values 
without lesions 0.2 -0.9210105 - 0.5210105 1h 0.6022 
without lesions 0.3 -0.8356043 - 0.2356043 1.5h 0.2803 
without lesions 0.4 -1.257698 - 0.4576978 2h 0.3248 
without lesions -0.35  -0.62526265 – 0.52526265 reperfusion time 0.2557 
without lesions 0.1272727 -0.4530022 - 0.1984567 interaction 0.4339 
 
4. Discussion 
The following clinical situations show the association between 
ischemia and OE. Ergenoglu et al [9] revealed higher scores for follicular 
degeneration and edema (p < 0.0001) in IR-induced ovarian sections 
treated with edaravone compared with sham ones in female Sprague 
Dawley rats. Chuderland et al[10] explained that ovarian 
hyperstimulation syndrome (OHSS) is induced by the ovarian release of 
a vasoactive, angiogenic substance that results in vascular 
hyperpermeability, leakage, and shift of fluids from blood vessels into 
the extravascular space with consequent ascites and edema, attributed 
to vascular endothelial growth factor (VEGF) in mice. Kline et al[11] 
included massive edema among other nonneoplastic conditions of the 
ovary that may present as adnexal masses. Seidman et al [12] noticed 
edema, congestion, and dilated lymphatic channels characterizing the 
tubal-peritoneal junction as a potential site of carcinogenesis in fallopian 
tube specimens. Cansu et al [13] determined that valproic acid (VPA) and 
oxcarbazepine (OXC) increased apoptosis and intracytoplasmic edema in 
female prepubertal Wistar rats 21-24 days old. Hosfield et al [14] noticed 
that long-term peritoneal dialysis develops edema of the peritoneal 
membrane, but the morphologic effects on the organs of female genital 
tract are obscure. Lubo-Palma et al [15] evaluated the edema of 
cadmium both in ovary cortex and in interfollicular zone of Swiss albino 
healthy females mice. Khalbuss et al [16] described the first case of an 
ovarian serous cystadenoma associated with a massive ovarian edema in 
a 17-year-old female. The solid mass had an intact capsule and diffuses 
interstitial edema, preserving the overall structure of the ovary and 
sparing the outer cortex. Gordon et al[17] noticed one patient (1.12%) 
among ten who withdrew because of edema related with the drug stealth 
liposomal doxorubicin in platinum- and paclitaxel-refractory ovarian 
cancer. Young et al [18] discussed tumors that occur in pregnancy which 
often have prominent intercellular edema. Espey et al[19] detected 
loosening of the connective tissue elements and some indication of 
edema at the apex of the mature follicles during the ovulatory process in 
indomethacin-treated rabbits compared with normal prostaglandin 
synthesis ovulatory follicles. Volkova OV et al [20] demonstrated that the 
structure of follicular components such as internal ovulation is 
accompanied with increasing interstitial edema. Motta et al [21] 
observed that fluidlike material was to (1) infiltrate the connective tissue 
of the tunica albuginea, (2) accumulate under the basal lamina, (3) 
distend intercellular spaces of the superficial epithelium and (4) a local 
increase of fluids (edema) may be an important factor in the final 
decomposition of the distended and weakened apex of the preovulatory 
follicle. Cherney et al[22] noticed extensive edema followed by rupture 
of the follicular wall within 10 hours after copulation in the apex of 
rabbit ovarian follicles.  
The following situations show the association between Epo 
and ischemic ovaries. Mahmoodi et al [23] found that Epo reduced IR 
injury and free radical production, increasing follicle survival and 
function in transplanted ovarian tissue. Sayyah-Melli et al[24] 
determined that rEpo was effective in reducing the oxidative damage of 
ovarian torsion in operated patients, 18-35 years old, with signs and 
symptoms of ovarian torsion. Karaca et al[25] evaluated the Epo 
administration as effective in reversing tissue damage induced by IR in 
ovaries of adult female rats. Suzuki et al [26] demonstrated that 
administration of asialo Epo could effectively enhance the survival of the 
follicles of transplanted cryopreserved ovaries in frozen-thawed canine 
ovarian xenotransplantation. However, David et al [27] did not detect 
expression of Epo mRNA in porcine ovaries. Kristiansson et al [28] 
concluded that females with carbohydrate-deficient glycoprotein 
syndrome type I have primary ovarian failure, but the syndrome does 
not affect the terminal charged carbohydrate portion in Epo. Hyttinen JM 
et al [29] generated a transgenic calf from in vitro produced bovine 
embryos microinjected with a gene construct consisting of genomic 
sequences encoding human Epo. Kamiński M [30] claimed that apoptosis 
regulates the atrophy of completely developed organs, e.g. thymus, and 
the hormonal restructuring of ovaries and others but on the other hand, 
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the development of apoptosis is arrested by so called "survival factors" 
as Epo. 
 
5. Conclusion  
Epo administration showed a non-significant short-term 
recessing trend for OE scores without lesions alteration. Perhaps, a 
longer study time than 2 hours or a higher Epo dosage may reveal 
clearer and significant effects.    
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